ACER Acer Therapeutics Inc.

17.88
-1.1  -6%
Previous Close 18.98
Open 19.11
Price To Book 3.39
Market Cap 179747425
Shares 10,052,988
Volume 40,623
Short Ratio
Av. Daily Volume 25,195

SEC filingsSee all SEC filings

  1. 424B2 - Prospectus [Rule 424(b)(2)] 181199147
  2. EFFECT - Notice of Effectiveness 181199128
  3. S-3 - Registration statement under Securities Act of 1933 181173454
  4. 8-K - Current report 181173417
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173132

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced October 29, 2018.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
NDA filing planned for 2019.
ACER-001
Urea cycle disorder (UCD)

SEC Filings

  1. 424B2 - Prospectus [Rule 424(b)(2)] 181199147
  2. EFFECT - Notice of Effectiveness 181199128
  3. S-3 - Registration statement under Securities Act of 1933 181173454
  4. 8-K - Current report 181173417
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173132
  6. 8-K - Current report 181173032
  7. 8-K - Current report 181142882
  8. 8-K - Current report 181085744
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 181073734
  10. 8-K - Current report 181051316